Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents

Nick C. Patel, M. Lynn Crismon, Kimberly Hoagwood, Peter S. Jensen

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The aim of this paper was to discuss the arguments for and against the use of atypical antipsychotics in children and adolescents with aggression, and provide recommendations for future research. A MEDLINE search (1985-2004) was performed to identify key literature. Search terms included, but were not limited to, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, children, and adolescents. The search was limited to English-language literature and randomized controlled trials. The use of atypical antipsychotics in children and adolescents has increased significantly over the past few years. Atypical antipsychotics are associated with a more favorable side-effect profile, and growing evidence supports their efficacy for aggression in this population. However, the long-term effects of these agents are unknown. No head-to-head evidence exists to suggest whether pharmacological or nonpharmacological treatments are superior for managing aggression associated with childhood and adolescent psychiatric and behavioral conditions. Future research of atypical antipsychotics in children and adolescents needs to evaluate not only the efficacy but also the effectiveness. Examination of treatment mediators and moderators may help to optimize treatment regimens and improve patient outcomes. Finally, effective interventions require the development and implementation of evidence-based treatment strategies using a multidisciplinary approach.

Original languageEnglish (US)
Pages (from-to)270-284
Number of pages15
JournalJournal of Child and Adolescent Psychopharmacology
Volume15
Issue number2
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Antipsychotic Agents
Aggression
olanzapine
Adolescent Psychiatry
Risperidone
Clozapine
Therapeutics
MEDLINE
Language
Randomized Controlled Trials
Pharmacology
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. / Patel, Nick C.; Crismon, M. Lynn; Hoagwood, Kimberly; Jensen, Peter S.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 15, No. 2, 04.2005, p. 270-284.

Research output: Contribution to journalArticle

Patel, Nick C. ; Crismon, M. Lynn ; Hoagwood, Kimberly ; Jensen, Peter S. / Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. In: Journal of Child and Adolescent Psychopharmacology. 2005 ; Vol. 15, No. 2. pp. 270-284.
@article{c5ff9b6299994ba09e4ec55dc44ec922,
title = "Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents",
abstract = "The aim of this paper was to discuss the arguments for and against the use of atypical antipsychotics in children and adolescents with aggression, and provide recommendations for future research. A MEDLINE search (1985-2004) was performed to identify key literature. Search terms included, but were not limited to, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, children, and adolescents. The search was limited to English-language literature and randomized controlled trials. The use of atypical antipsychotics in children and adolescents has increased significantly over the past few years. Atypical antipsychotics are associated with a more favorable side-effect profile, and growing evidence supports their efficacy for aggression in this population. However, the long-term effects of these agents are unknown. No head-to-head evidence exists to suggest whether pharmacological or nonpharmacological treatments are superior for managing aggression associated with childhood and adolescent psychiatric and behavioral conditions. Future research of atypical antipsychotics in children and adolescents needs to evaluate not only the efficacy but also the effectiveness. Examination of treatment mediators and moderators may help to optimize treatment regimens and improve patient outcomes. Finally, effective interventions require the development and implementation of evidence-based treatment strategies using a multidisciplinary approach.",
author = "Patel, {Nick C.} and Crismon, {M. Lynn} and Kimberly Hoagwood and Jensen, {Peter S.}",
year = "2005",
month = "4",
doi = "10.1089/cap.2005.15.270",
language = "English (US)",
volume = "15",
pages = "270--284",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents

AU - Patel, Nick C.

AU - Crismon, M. Lynn

AU - Hoagwood, Kimberly

AU - Jensen, Peter S.

PY - 2005/4

Y1 - 2005/4

N2 - The aim of this paper was to discuss the arguments for and against the use of atypical antipsychotics in children and adolescents with aggression, and provide recommendations for future research. A MEDLINE search (1985-2004) was performed to identify key literature. Search terms included, but were not limited to, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, children, and adolescents. The search was limited to English-language literature and randomized controlled trials. The use of atypical antipsychotics in children and adolescents has increased significantly over the past few years. Atypical antipsychotics are associated with a more favorable side-effect profile, and growing evidence supports their efficacy for aggression in this population. However, the long-term effects of these agents are unknown. No head-to-head evidence exists to suggest whether pharmacological or nonpharmacological treatments are superior for managing aggression associated with childhood and adolescent psychiatric and behavioral conditions. Future research of atypical antipsychotics in children and adolescents needs to evaluate not only the efficacy but also the effectiveness. Examination of treatment mediators and moderators may help to optimize treatment regimens and improve patient outcomes. Finally, effective interventions require the development and implementation of evidence-based treatment strategies using a multidisciplinary approach.

AB - The aim of this paper was to discuss the arguments for and against the use of atypical antipsychotics in children and adolescents with aggression, and provide recommendations for future research. A MEDLINE search (1985-2004) was performed to identify key literature. Search terms included, but were not limited to, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, children, and adolescents. The search was limited to English-language literature and randomized controlled trials. The use of atypical antipsychotics in children and adolescents has increased significantly over the past few years. Atypical antipsychotics are associated with a more favorable side-effect profile, and growing evidence supports their efficacy for aggression in this population. However, the long-term effects of these agents are unknown. No head-to-head evidence exists to suggest whether pharmacological or nonpharmacological treatments are superior for managing aggression associated with childhood and adolescent psychiatric and behavioral conditions. Future research of atypical antipsychotics in children and adolescents needs to evaluate not only the efficacy but also the effectiveness. Examination of treatment mediators and moderators may help to optimize treatment regimens and improve patient outcomes. Finally, effective interventions require the development and implementation of evidence-based treatment strategies using a multidisciplinary approach.

UR - http://www.scopus.com/inward/record.url?scp=19544392160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19544392160&partnerID=8YFLogxK

U2 - 10.1089/cap.2005.15.270

DO - 10.1089/cap.2005.15.270

M3 - Article

VL - 15

SP - 270

EP - 284

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 2

ER -